New chemo combo shows promise for tough lung cancer

NCT ID NCT07640932

Not yet recruiting Disease control Sponsor: Yonsei University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests whether adding lurbinectedin to paclitaxel works better than paclitaxel alone for people with advanced small cell lung cancer that has returned after first treatment. About 69 adults will be randomly assigned to one of two groups. The study measures how many patients' tumors shrink and how long they live without the cancer growing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lurbinectedin and paclitaxel (chemotherapy drugs)
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced small cell lung cancer whose disease has worsened after initial chemotherapy.
What could go wrong: This is a small, early-phase (Phase 2) trial with only 69 participants, so results may not apply to everyone. The combination may cause more side effects than paclitaxel alone, and it is not a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, SMALL CELL LUNG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, SMALL CELL LUNG

Contacts and locations

Locations

Yonsei University Health System, Severance Hospital

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.